10jili. com

10jili. com National Beverage (NASDAQ:FIZZ) Sets New 1-Year Low – Should You Sell?Former President Jimmy Carter, a man who redefined what a post-presidency could be, died Sunday. Dec. 29. He was 100. Carter, who lived longer than any other U.S. president, entered home hospice care in Plains, Georgia, in February 2023 after a series of short hospital stays. Carter had the longest post-presidency of anyone to hold the office, and one of the most active. After a one-term presidency, which ended with low approval ratings, Carter emerged as a champion of human rights and worked for several charitable causes. Carter founded the Carter Presidential Center at Emory University in Atlanta. The center, which began in 1982, is devoted to issues relating to democracy and human rights. The only Georgian ever elected to the White House, Carter left office after a single term that was highlighted by forging peace between Israel and Egypt, but was overshadowed by the Iran hostage crisis. In the decades after, his reputation grew through his and wife Rosalynn Carter’s work at the Carter Center in Atlanta and his philanthropic causes such as Habitat for Humanity. “People will be celebrating Jimmy Carter for hundreds of years. His reputation is only going to grow,” Rice University history professor Douglas Brinkley wrote in his book “The Unfinished Presidency of Jimmy Carter.” In 1986, The Carter Center began leading an international campaign to eradicate Guinea worm disease. The disease may soon become the second human disease in history, after smallpox, to be eradicated. Since 1984, Carter worked with Habitat for Humanity International, an organization that works worldwide to provide housing for underprivileged people. James Earl Carter Jr. was born in Plains on Oct. 1, 1924, the first of four children of Earl Carter, a farmer and businessman, and Lillian Gordy Carter, a registered nurse. Related: Jimmy Carter turns 99 with family around him He gained an appointment to the U.S. Naval Academy, graduated and joined the Navy submarine branch where in seven years he worked his way into “Rickover’s boys,” the elite nascent unit of America’s nuclear submarine fleet championed by the iconic Admiral Hyman Rickover. Carter was on his way up until a death at home changed his destiny. His father Earl, a farmer, businessman and cornerstone personality in the Plains community, died from cancer. Carter left the Navy and its far-from-Plains postings such as Hawaii, and he, Rosalynn and their growing family returned to Georgia in 1953 to take over the family farming business. It was there he first ran for school board, then state senator. He was elected governor in 1970. Carter served one successful term before launching an improbable bid to become president, winning the Democratic nomination and then defeating Republican President Gerald Ford in November 1976. On his inauguration day, rather than driving past the crowds in an armored limousine, Jimmy and Rosalynn emerged from the car with daughter Amy at their side and walked down Pennsylvania Avenue, holding hands and waving. Carter’s successes included promoting human rights, adding to the national park and preserve system, reestablishing governmental credibility after the Watergate Crisis, and the Camp David Accords, which forged a peace agreement between Egypt and Israel. They were overshadowed by trouble at home and abroad. At home, Carter and his advisers, most of them Washington outsiders, met resistance from his own party. Then, in November 1979, Iranian militants stormed the U.S. Embassy in Tehran and took hostages. He tried negotiation, then launched a bold rescue mission that never reached its target because of helicopter failure. He could not resolve the situation until the last day of his administration. At home, a foundering economy exacerbated by oil embargoes from Mideast countries and the rise of the Republican Party under Ronald Reagan helped lead to his defeat in November 1980. Carter returned to tiny Plains and used the power of an ex-president’s bully pulpit as the springboard to his last, and, some say, his best act. Carter began volunteering for Habitat for Humanity, a fairly new Americus-based organization, building houses for the poor. Then, together with Rosalynn, he founded the Atlanta-based Carter Center, which focused on making peace and spreading health and democracy around the world. It will carry the couple’s humanitarian and democratic work forward. From his work as president and as the leader of the Carter Center, he won the Nobel Prize, the United National Human Rights Prize and many other notable awards from countries, organizations and world leaders. The Carters both were awarded the Presidential Medal of Freedom by President Bill Clinton. ”Jimmy and Rosalynn Carter,” Clinton said, “have done more good things for more people in more places than any other couple on the face of the Earth.” Rosalynn Carter, Jimmy Carter’s wife of 77 years, died in November 2023 . They are survived by their children Amy, Chip, Jack and Jeff; 11 grandchildren; and 14 great-grandchildren. Sources: Cartercenter.org, Plains Historical Preservation Trust, The Associated Press; The Brookings Institution; U.S. Navy; WhiteHouse.gov, Gallup

If you’re deep into comparison shopping for fitness watches, you’ve probably come across some debate on the different display technologies. Manufacturers are moving toward AMOLED style screens (bright! Colorful! Sharp! Modern!) while some longtime users are diehards for the older MIP or LCD style screens (the general vibe is: pry them out of my cold dead hands). So where does that leave you, the shopper, wondering what to get for your first or next watch? I’m going to break down all the pros and cons. What’s the difference between MIP and AMOLED displays? I’m going to gloss over a lot of the detail you’d need to be an engineer to love and concentrate on what it’s like to use these screens. With that in mind: AMOLED displays have tiny pixels that glow to create the display, leaving black areas where the pixels are not turned on. (Your phone’s screen is probably AMOLED.) AMOLED displays are full color, and they use power any time they’re on. They’re bright and highly visible in the dark, but can potentially get washed out in extremely bright sunlight. MIP displays (memory-in-pixel), also called memory LCD, do not light up on their own. These displays reflect light, much like old-school LCD watches, so they are highly visible in sunlight but require a backlight to be seen in the dark. They can display color, but only a limited range of colors and they are not as vibrant or as high-resolution as AMOLED screens. AMOLED displays tend to be higher resolution, brighter, and sharper. MIP displays look more old-fashioned, but they always look good in bright sunlight, and they can be always-on without running down the battery life (assuming you have the backlight turned off). AMOLED displays tend to be touchscreens, but MIP displays can have touchscreens as well. For example, the Coros Pace 3 has a touchscreen, while the Garmin Forerunner 55 does not. (If you don’t want a touchscreen, you should know that you can disable the touchscreen on most sports watches.) Which watches have MIP and which have AMOLED displays? We’re currently at a transition point where most manufacturers are moving toward AMOLED if they haven’t switched already. Any fancy-looking smartwatch is likely to be AMOLED; there’s no MIP Apple Watch, for example. But among sports watches, there are plenty of models with MIP displays still being sold new. Here’s a breakdown of some of the more popular watches: AMOLED (or similar) displays: Apple Watch Samsung Galaxy Watch Pixel Watch Fitbit Charge 5 and Charge 6 Coros Pace Pro Garmin Forerunners 165, 265, and 965 Garmin Vivoactive 5 Garmin Venu 2 and 3 Garmin Fenix 8 AMOLED Polar Vantage, Ignite 3, Grit X2 Pro Suunto Race MIP (or similar) displays: Coros Pace 3, Apex 2, Apex 2 Pro, Vertix 2 (everything except the Pace Pro) Garmin Forerunners 55, 255, 955, and any other Forerunner not ending in -65 Garmin Instinct (this is actually not MIP but a regular 2-color LCD) Garmin Vivoactive 4 Garmin Fenix 7 Garmin Fenix 8 Solar Polar Pacer, Pacer Pro, Grit X, Grit X Pro Suunto Core, 9 Baro, 9 Peak Real-world visibility tests I’ve been reviewing watches nonstop for a few months now, mostly AMOLED models, so I was surprised when I dug into the running watch forums and found people saying they would never upgrade to an AMOLED watch because they just aren’t readable in sunlight. Huh? Every AMOLED watch I’ve tested has been great in the sun. But OK, maybe there was something I was missing. Ever since I read those posts, I’ve been paying attention to visibility, the better to form my own opinions. I got into the difference in display types in my comparison between the Coros Pace 3 (MIP) and Pace Pro (AMOLED) , for example. And for today’s analysis, I’ve also borrowed a Forerunner 55 (MIP) to compare to my Forerunner 265S. So let’s take a look. In bright sunlight, at the right angle, MIP has a slight edge This is the best case for MIP superiority, and it comes with caveats, so let’s enjoy it while we can. When you have bright light shining directly on a MIP screen, it practically glitters. Modern AMOLEDs tend to be pretty bright as well, but on the brightest of days in the directest of sunlight, they can be a bit washed out. That said, AMOLEDs don't show up well in photos on sunny days, so I don't think the photo above really does the AMOLED screen justice. (Those black horizontal lines on the AMOLED are also an artifact of the camera taking the picture faster than the display could refresh; they're not visible in real life.) I didn’t have a lot of great side-by-side photos in sunlight, so for another test I put both Forerunners directly under a bright desk lamp. A desk lamp is not the sun. However, I feel like this is a better demonstration of typical conditions—as judged by my own personal eyes and brain. Your own opinion might differ. If you're making your shopping decision based on how the displays look in sunlight, trying them out in person will tell you a lot more than any photo will. (Underrated shopping tip: show up to a running club and ask everybody about their watch. They'll be more than happy to show them off.) In shadow (even on a sunny day), AMOLED stays visible I went for a few runs on bright sunny days with both of the Coros watches, and found I actually preferred the AMOLED display even in the sun. That’s because sunny days are also days with deep shadows. You have to get the angle just right to get that bright glittery effect on a MIP screen. But an AMOLED will shine from the shadows. Most of the time, either my body or the screen’s own bezel was shading it a bit. The photo above was taken on the same day, same run, as the outdoor Coros photo in sunlight. The sun didn't go behind a cloud, I was just standing in a different position. And the photo here is the exact same setup with the desk lamp, but with the watches angled just a few degrees downward. Drastic difference in readability. Now, if you’re used to MIP watches, you’re used to angling them into the sun to get a good look. If you’re fine with that, great. I prefer the AMOLED in this situation. In medium-light scenarios, both are good Here are both watches outdoors, on an overcast day, displaying the kind of screen you'd see most often during a running or other sports activity. This is probably the most telling photo of all: they are both fine. The MIP watch makes up for its potential visibility issues by defaulting to a white background, and the AMOLED just keeps showing bright numbers on a dark screen like usual. I use the AMOLED (the 265S) in this photo for most of my runs—it's not a review unit, it's the watch I actually own—and it's always visible, always looks great, in any weather and with or without sunglasses. But the MIP? It's good too! Nobody loses points here. In the dark, both screens light up just fine You probably expected me to say that AMOLED is better in the dark. Honestly, while AMOLED is prettier in the dark (and prettier almost anytime, because AMOLED displays tend to be much higher resolution), both screens are equally readable. The same gesture that wakes the AMOLED screen can wake the MIP screen’s backlight. (Please note that both watches are much sharper than the photo in real life. The blur you're seeing is just me failing to hold the camera perfectly steady in a dark room.) In actual darkness, like when you’re putting your kids to bed, your best bet is an AMOLED watch with a “sleep mode” that displays the time dimly. That way you don’t need to turn on a backlight to see the time. So if you’re concerned about the light being too bright, you probably want AMOLED. Battery usage MIP diehards like to say that MIP screens are more battery efficient. That may be technically true, but nobody buys a watch based on the battery life of its display . We want to know about the battery life of the entire watch . And honestly, AMOLED watches tend to have just as good a battery life as their MIP counterparts. Whether it’s better battery technology, power savings elsewhere in the software or hardware, or AMOLED itself being more efficient than you’d expect, it doesn’t matter. The Forerunner 965 (AMOLED) and the Forerunner 955 (MIP) both have a battery life of 8.5 hours during an activity with multi-band GPS mode and music playing. In smartwatch mode (not tracking activities), the 965 lasts 23 days in smartwatch mode, compared to 15 days for the 955. In other words, the AMOLED watch lasts eight days longer . If battery life is your priority, in this situation you’d want the AMOLED. This will vary by model, of course. Look up the battery life specs for the specific watches you’re interested in. Maybe the MIP model will last longer, but maybe the AMOLED will. Don’t make assumptions about the battery based on the look of the screen. How to make a decision You've seen my photos and heard my opinions, but ultimately you need to make a decision for yourself. And of the two display types, I'll be honest: neither is unusable or terrible or has some horrific misfeature that should be a dealbreaker. I do think that most people will prefer the AMOLED style. But if you end up with a MIP display, it will be fine . So let me run through a few things to keep in mind: If you already have a MIP watch and love it , I wouldn’t fault you for sticking with MIP. You already know the downsides and you don’t mind them. If you love a MIP watch but are afraid that you wouldn’t like an AMOLED watch , don’t let that stop you from shopping AMOLED models. The downsides of AMOLED (as the internet tells them) are wildly exaggerated. If you have seen both watches in person , in a wide variety of lighting conditions, and have a strong opinion, just go with your preference. If you’re new to all of this and feeling confused right now , you’ll probably like AMOLED better. All the new watches are AMOLED anyway. If your dream watch needs to be an older MIP watch to fit in your budget , go ahead and get it. It will be fine. That last point is one where you’ll want to do some math. Often you can get an older generation of a feature-rich watch for the same price as the newest generation of a more barebones model. That’s the case right now for a lot of Garmin models, where pretty much everything released in the last year or so has an AMOLED screen, and everything before it is MIP. For example, looking only at the newest models, the Forerunner 965 is a more feature-rich watch than the 265, and costs $599 versus $449. But if you went a generation back and got the Forerunner 955 , with a MIP screen, that watch is available right now for $399—which is $50 less than the new, AMOLED Forerunner 265 . Worth it? That’s your call. But a lot of people would go for the 955, if they care about the 9xx series features (like maps and skiing features) more than they care about the screen. And now that you've seen the photos and read my deep dive, you're able to make that decision for yourself.A resident of Swaddi Kalan village here has become the first woman drone pilot in her area for spraying pesticides, an accomplishment that she believes will enable her to make a decent living besides inspiring other women. Arvinder Kaur, wife of Jagrup Singh, underwent a special training from Chambal Fertilizer Company and she was given a drone for spraying pesticides on crops. Now, she is known in her area for spraying pesticides on crops using drones. Spraying one acre of land using a drone costs only ₹ 300 and takes only 7 minutes, she said. She said that the drone spray technology has brought a revolutionary change in the agricultural sector, which should be adopted by more farmers. This technology not only saves pesticides and time but also enables spraying of one acre of crop in just seven minutes. This technology has resulted in an increase of about 15% crop yield. Arvinder Kaur is a member of a self-help group (SHG) under the Punjab State Rural Livelihood Mission. Block programme manager Navdeep Singh motivated her to undergo drone training. Subsequently, she underwent 10 days of special training at the DGCA (directorate general of civil aviation) training centre in Manesar, Gurugram, and got a drone pilot certificate. Arvinder said that adopting this technology saves both time and money. She expressed her happiness in working in this field and encouraged other women to join her. Arvinder appealed to the women of Punjab to work shoulder to shoulder with their families, adopting modern technology in farming to make the agricultural business profitable. Block programme manager Navdeep Singh said women of Siddhwan Bet block are engaged in preparing various products, such as pickle, papad, vermicompost, phulkari, soap, candles, makki ki roti, sarson ka saag and turmeric cakes (haldi ki pinni). These products are sold through stalls at fairs and various shops, as well as online platforms. Sarpanch Jagdeep Singh Khalsa praised Arvinder Kaur, saying that she has brought fame to the Swaddi Kalan village by learning the art of flying drones. This will inspire and motivate other women, she added.

HubSync Revolutionizes Tax and Accounting with 2024 Product Enhancements & New FeaturesWorld number one Luke Humphries continued his bid for back-to-back World Championship titles after easing through to the last 16. While there was high drama in Alexandra Palace on the first day back after the Christmas break, where Damon Heta threw a nine-dart finish, Humphries enjoyed a serene evening. He beat Nick Kenny 4-0 to set up a mouth-watering fourth-round meeting with two-time champion Peter Wright. THE WORLD NUMBER ONE KICKS ON! Luke Humphries comfortably books his spot in the Last 16 with a 4-0 whitewash victory over Nick Kenny, averaging 98.59! 📺 https://t.co/pIQvhqYxEj #WCDarts pic.twitter.com/XAADalXD4Q — PDC Darts (@OfficialPDC) December 27, 2024 Kenny was unable to produce the form that saw him beat Raymond van Barneveld in the previous round and Humphries did not need to be anywhere near his best. “It was one of those games I didn’t want to take for granted,” he said. “I expected a tough game and I wasn’t firing, I felt there is so much more to give, I felt there was more to come out of me. “I didn’t want to give anyone an inch because they can take a mile. “I’m not going to give up this world title without a fight, I wasn’t at my best but when someone pushes me I know I can come up with the goods.” Earlier in the day Heta set the tournament alight on its resumption with a stunning nine-dart finish before bowing out. The Australian, seeded ninth, achieved darting perfection in the second set of his match with Luke Woodhouse to earn a cool £60,000 payday. However, his joy was short-lived as Woodhouse won a thrilling battle 4-3, having trailed 3-1. HEROIC HETA HITS THE NINE! 🔥 UNBELIEVABLE SCENES! 🤯 Damon Heta lands the second nine-darter of the tournament to raise the roof at Alexandra Palace! #WCDarts pic.twitter.com/DW6rhvFqez — PDC Darts (@OfficialPDC) December 27, 2024 Heta was millimetres away from throwing a nine-darter in the previous round when he missed the double 12, but he made no mistake this time in the first match after the Christmas break. Heta’s feat was the second time a nine-darter has been thrown in the 2025 tournament and the 16th of all time at the World Championship, following Christian Kist’s effort before Christmas. As well as landing the Australian a hefty payday, it also saw a lucky fan in Ally Pally win a £60,000, with £60,000 also being donated to Prostate Cancer UK. There were several other titanic battles, none better than Gerwyn Price’s sudden-death leg victory over Joe Cullen. Price looked like he was going to have an easy night when he coasted into a 3-0 lead, but Cullen hit back to send it to a decider, which went all the way. Cullen landed a ‘Big Fish’ 170 checkout to send the tie to a sudden-death leg on his throw but Price hit some big numbers to steal victory. “That was tough, I just wanted to get over the winning line,” he said during his on-stage interview. PRICE WINS A THRILLER! That might just be the game of the tournament so far! 💥 Gerwyn Price manages to break the Rockstars throw in the final leg of the game, and beats Joe Cullen 4-3 and books his place in the Last 16! 📺 https://t.co/pIQvhqYxEj #WCDarts pic.twitter.com/VnjnJxP0T0 — PDC Darts (@OfficialPDC) December 27, 2024 “He kept coming back, the crowd were way behind him. “I thought I was going to lose, but I kept in there right to the end and got the win. “He played some good darts at the right times. I put myself in that position, I got myself out of it and I’m still in.” Seventh seed Jonny Clayton also battled to victory after squandering a 3-0 lead against Daryl Gurney. Gurney then had six darts to send the decider to a tiebreaker but lost his nerve and Clayton stole a 4-3 win. Stephen Bunting and Peter Wright, who was suffering from a chest infection, enjoyed much more safe passages with routine wins over Madars Razma and Jermaine Wattimena respectively.OneDigital Investment Advisors LLC purchased a new stake in Viking Therapeutics, Inc. ( NASDAQ:VKTX – Free Report ) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 3,260 shares of the biotechnology company’s stock, valued at approximately $206,000. Other institutional investors have also recently modified their holdings of the company. Oak Ridge Investments LLC acquired a new position in Viking Therapeutics during the third quarter worth about $837,000. Oppenheimer & Co. Inc. boosted its stake in shares of Viking Therapeutics by 43.5% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 102,324 shares of the biotechnology company’s stock worth $6,478,000 after acquiring an additional 31,011 shares in the last quarter. Nvwm LLC acquired a new stake in shares of Viking Therapeutics in the 3rd quarter worth approximately $999,000. Chartwell Investment Partners LLC grew its holdings in shares of Viking Therapeutics by 88.0% in the 3rd quarter. Chartwell Investment Partners LLC now owns 36,666 shares of the biotechnology company’s stock worth $2,322,000 after acquiring an additional 17,159 shares during the period. Finally, Aptus Capital Advisors LLC increased its stake in Viking Therapeutics by 34.1% in the 3rd quarter. Aptus Capital Advisors LLC now owns 38,143 shares of the biotechnology company’s stock valued at $2,415,000 after purchasing an additional 9,699 shares in the last quarter. 76.03% of the stock is currently owned by hedge funds and other institutional investors. Analyst Ratings Changes Several research firms have weighed in on VKTX. Morgan Stanley reissued an “overweight” rating and issued a $105.00 target price on shares of Viking Therapeutics in a report on Thursday, September 12th. JPMorgan Chase & Co. started coverage on shares of Viking Therapeutics in a research note on Wednesday, September 11th. They issued an “overweight” rating and a $80.00 price objective on the stock. StockNews.com upgraded shares of Viking Therapeutics to a “sell” rating in a research report on Tuesday, October 15th. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a report on Wednesday. Finally, Oppenheimer reissued an “outperform” rating and set a $138.00 price objective on shares of Viking Therapeutics in a research note on Wednesday, September 25th. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $109.73. Insider Activity In related news, Director Lawson Macartney sold 2,000 shares of Viking Therapeutics stock in a transaction on Friday, November 8th. The stock was sold at an average price of $68.67, for a total value of $137,340.00. Following the transaction, the director now owns 47,965 shares in the company, valued at approximately $3,293,756.55. This trade represents a 4.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, Director J Matthew Singleton sold 10,300 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $69.50, for a total value of $715,850.00. Following the sale, the director now owns 9,500 shares of the company’s stock, valued at $660,250. This represents a 52.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold a total of 371,117 shares of company stock valued at $27,140,009 in the last 90 days. 4.70% of the stock is currently owned by insiders. Viking Therapeutics Stock Performance Shares of VKTX opened at $52.59 on Friday. Viking Therapeutics, Inc. has a fifty-two week low of $11.55 and a fifty-two week high of $99.41. The company has a market capitalization of $5.86 billion, a PE ratio of -56.55 and a beta of 1.00. The stock has a fifty day moving average of $63.73 and a two-hundred day moving average of $60.38. Viking Therapeutics ( NASDAQ:VKTX – Get Free Report ) last released its earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.02. During the same period last year, the business earned ($0.23) earnings per share. As a group, equities research analysts forecast that Viking Therapeutics, Inc. will post -0.98 earnings per share for the current fiscal year. Viking Therapeutics Profile ( Free Report ) Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. Further Reading Five stocks we like better than Viking Therapeutics How to Use High Beta Stocks to Maximize Your Investing Profits Vertiv’s Cool Tech Makes Its Stock Red-Hot How to Capture the Benefits of Dividend Increases MarketBeat Week in Review – 11/18 – 11/22 3 REITs to Buy and Hold for the Long Term 2 Finance Stocks With Competitive Advantages You Can’t Ignore Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics, Inc. ( NASDAQ:VKTX – Free Report ). Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .

AP News in Brief at 6:04 p.m. EST

Heartwarming video shows shelter dog with no adoption applications picking Christmas toy

Engineer pleads not guilty in US case of deadly Iran-linked drone strikeIRVINE, Calif. , Dec. 19, 2024 /PRNewswire/ -- OrthAlign, Inc. today announced a significant milestone with the successful first clinical use of its Lantern Hip handheld technology. The procedure was performed by Edwin Su, MD, a renowned orthopedic surgeon at the Hospital for Special Surgery (HSS) in New York, NY . "The first clinical case of Lantern Hip is a monumental achievement for our team and the surgeons involved with this project," said Eric Timko , CEO of OrthAlign. "This expansion of our flagship platform to include hips not only enhances our product portfolio, but also positions us for significant growth in both the hospital and the ambulatory surgery center (ASC). We're excited to kick off the new year with Lantern Hip and showcase its impact at the American Academy of Orthopaedic Surgeons annual meeting," says Eric Timko . Lantern Hip is the latest evolution in hip technology, built upon the success of over 375,000 OrthAlign procedures worldwide. Next-generation sensors, powered by accelerometers and gyroscopes, are designed to provide an accurate and simple solution to navigate cup placement and measure changes in leg length and offset. The system enables the surgeon to choose their preferred implant, and is accessible to any site of service. "Lantern Hip allows me to personalize cup position for each patient," said Dr. Su. "I can compare the functional pelvic plane (FPP), the anterior pelvic plane (APP), and the coronal plane during live cup navigation, so I can place the implant in the best position for function and stability. With its triple-sensor technology, Lantern Hip also allows me to feel confident in my leg length and offset restoration. The system was simple for me and my team to integrate into our workflow during our first case, and I expect this will make a positive impact on other surgeons' experience too." OrthAlign will continue to offer surgeons the opportunity to experience Lantern Hip firsthand through webinars and demonstrations at industry events throughout 2025. For inquiries about upcoming events or to schedule a product demonstration, contact your local OrthAlign representative. Visit www.orthalign.com/lanternhip to view the Lantern Hip introductory video. Lantern Hip is indicated for use in direct anterior total hip arthroplasty procedures with the patient in the supine position. About OrthAlign, Inc. OrthAlign is a medical device company with a focus on delivering practical, cutting-edge technologies for orthopedic surgery. With a commitment to innovation and excellence, OrthAlign provides surgeons with user-friendly, cost-effective solutions to help improve patient care in joint replacement. In 2023, the company celebrated a record-breaking year with over $50 million in global revenue, reflecting its dedication to growth and leadership in the industry. Driven by the belief that everyone deserves exceptional healthcare, OrthAlign is committed to making empowering technologies accessible to all. LANTERN ® and ORTHALIGN ® are registered trademarks of OrthAlign, Inc. View original content to download multimedia: https://www.prnewswire.com/news-releases/orthalign-inc-announces-first-cases-using-lantern-hip-the-next-evolution-in-total-hip-replacement-technology-302336610.html SOURCE OrthAlign

They were accused of 'ruining people's lives'...but what do people think now?Global X MLP & Energy Infrastructure ETF (NYSEARCA:MLPX) Sees Unusually-High Trading Volume – Here’s Why